AKT1 and idiopathic pulmonary fibrosis: The Omipalisib trial has already demonstrated the feasibility of using p-Akt levels in bronchoalveolar lavage (BAL) fluid macrophages to track target engagement in IPF patients, indicating its relevance as a transferable biomarker (65).